Skip to main content
Premium Trial:

Request an Annual Quote

Olink Bioscience Snags China Distributor

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Uppsala, Sweden-based Olink Bioscience has allied with Beijing Pioneer Medical Instrument (PioneerBiomed) to distribute its protein research technology in China.

Under the agreement, PioneerBiomed will distribute Olink Bioscience's Duolink product line to its clients in academic, clinical, and government labs, and to biotechnology and pharmaceutical customers.

The Duolink line uses the firm's in situ proximity ligation assay technology to extend the capabilities of protein applications to include direct detection of proteins, protein interactions, and modifications. The technology enables researchers to detect target proteins at single-molecule resolution and to study them at normal expression levels in fixed cells and tissue sections.

Olink Biosciences Director of Sales and Marketing Peter Karlberg said that the distribution pact "represents a huge commercial opportunity" that will "bring us valuable new business in the academic and the biotech/pharmaceutical industry throughout the country."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.